BIO’s report on the vaccine pipeline—just released today—explores the need for more investment and more research into novel pathogens. Meanwhile, USDA has proposed regulatory changes to genetically engineered crops, but BIO explains why they’re too complicated. (514 words, 2 minutes, 34 seconds)
Witnesses told a Senate Judiciary hearing yesterday that predictable patent protection keeps U.S. an innovation leader—plus, a new study shows how updated COVID vaccines protect against thrombosis. (549 words, 2 minutes, 44 seconds)
A federal commission explains why biotech is a national security issue—plus, a recap of last week’s Davos and what BIO members said at the event. (575 words, 2 minutes, 52 seconds)
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the U.S. Senate Committee on Health, Education, Labor, and Pensions’ (Committee’s) Request for Information on Improving and Protecting Access to Gene Therapies (the RFI).
Legislation restoring R&D tax deductions advanced in the House Ways & Means Committee – it's a good time to
join the BIOAction campaign and ask your lawmaker to support it. Plus, BIO's CEO Rachel King says government meddling could end a golden age of new drugs, and a UCLA event today looks at the threat of AMR. (643 words, 3 minutes, 12 seconds)
In advance of the Agency's public workshop on Enhancing Adoption of Innovative Clinical Trial Approaches, BIO outlined specific considerations and plans to participate in the workshop.
COVID-19, flu, and RSV are here—but for the first winter ever, we have vaccines for all three. Meanwhile, USDA has awarded $19 million in grants to boost biofuels. (417 words, 2 minutes, 5 seconds)
BIO and the American Seed Trade Association submitted comments on USDA-APHIS' proposed exemptions of five types of genetic modifications a plant can contain and be exempt from regulations for the movement of organisms modified or produced through genetic engineering because the modifications could otherwise be achieved through conventional breeding.
Announcements around and during JPM Week each January often create waves throughout the biotechnology ecosystem. Join this webinar to learn what experienced dealmakers and market analysts found most relevant and influential from JPM Week to consider when planning your own capital formation and partnering priorities for 2024. Developments affecting M&A trends, the IPO window, licensing trends, and investor sentiment will all be discussed.
This webinar will also preview the program for the BIO CEO & Investor Conference, February 26-27, and explain how BIO’s One-on-One Partnering during the event can help you make progress against your 2024 priorities. Consider these insights when planning your own capital formation and partnering strategies for this year & get a preview of the program and BIO One-on-One PartneringTM tips for the upcoming BIO CEO & Investor Conference, February 26-27.
Speakers include:
-- Donna LaVoice (Moderator), President and CEO, LaVoieHealthScience
-- Evan Loh, MD, CEO, Paratek Pharmaceuticals
-- Kimberly Nearing, Venture Partner, BVCF
·-- Tim Opler, PhD, Managing Director, Global Healthcare Group, Stifel
